公开(公告)号：US20240271188A1

公开(公告)日：2024-08-15

申请号：US18614496

申请日：2024-03-22

Applicant: Murdoch Childrens Research Institute

Inventor： Howard Slater

IPC: C12Q1/6827 ,  C12Q1/6806 ,  C12Q1/6816 ,  C12Q1/6881

CPC classification number: C12Q1/6827 ,  C12Q1/6806 ,  C12Q1/6816 ,  C12Q1/6881 ,  C12Q2537/16

Abstract: Methods of measuring chimerism in a biological sample use informative copy number variations (CNV) in genetically distinct cell populations. Chimerism describes the co-existence of cells originating from more than one individual. Assessing CNV polymorphisms in genomic DNA provides a useful in-vitro method of measuring chimerism. The accuracy of the methods can be validated using an internal validation step.

公开(公告)号：US12060610B2

公开(公告)日：2024-08-13

申请号：US14089517

申请日：2013-11-25

Applicant: iRepertoire, Inc.

Inventor： Jian Han

IPC: C12Q1/6883 ,  C12Q1/686 ,  C12Q1/6869 ,  C12Q1/6881

CPC classification number: C12Q1/6883 ,  C12Q1/686 ,  C12Q1/6869 ,  C12Q1/6881 ,  C12Q2600/16 ,  C12Q1/686 ,  C12Q2549/119 ,  C12Q2537/143 ,  C12Q2525/155 ,  C12Q1/6869 ,  C12Q2549/119 ,  C12Q2531/113 ,  C12Q2525/155

Abstract: Disclosed is a method for amplifying RNA and/or DNA from immune cell populations and using the amplified products to produce an immune response profile and evaluate the possible correlation between a normal or abnormal immune response and the development of a disease such as an autoimmune disease, cancer, diabetes, or heart disease.

公开(公告)号：US20240254658A1

公开(公告)日：2024-08-01

申请号：US18593788

申请日：2024-03-01

Applicant: 10x Genomics, Inc.

Inventor： Jason Bell ,  Francesca Meschi ,  Geoffrey McDermott ,  Michael Schnall-Levin ,  Xinying Zheng

IPC: C40B30/04 ,  C07K14/74 ,  C12N15/10 ,  C12N15/11 ,  C12N15/85 ,  C12Q1/6804 ,  C12Q1/6806 ,  C12Q1/6818 ,  C12Q1/6827 ,  C12Q1/6881 ,  C40B50/06 ,  C40B70/00 ,  G01N33/50 ,  G01N33/53 ,  G01N33/532 ,  G01N33/543 ,  G01N33/548 ,  G01N33/569 ,  G01N33/58

CPC classification number: C40B30/04 ,  C07K14/70539 ,  C12N15/1037 ,  C12N15/1055 ,  C12N15/1065 ,  C12N15/1075 ,  C12N15/11 ,  C12N15/85 ,  C12Q1/6804 ,  C12Q1/6806 ,  C12Q1/6818 ,  C12Q1/6827 ,  C12Q1/6881 ,  G01N33/5032 ,  G01N33/505 ,  G01N33/5304 ,  G01N33/5306 ,  G01N33/5308 ,  G01N33/532 ,  G01N33/54306 ,  G01N33/54366 ,  G01N33/548 ,  G01N33/56977 ,  G01N33/58 ,  C12N2310/20 ,  C12N2320/10 ,  C12Q2537/164 ,  C12Q2563/179 ,  C12Q2563/185 ,  C12Q2565/1015 ,  C40B50/06 ,  C40B70/00

Abstract: Methods and systems are provided for sample preparation techniques and sequencing of macromolecular constituents of cells and other biological materials.

公开(公告)号：US12031183B2

公开(公告)日：2024-07-09

申请号：US16226270

申请日：2018-12-19

Applicant: The Board of Trustees of the Leland Stanford Junior University

Inventor： Aaron M. Newman ,  Arash Ash Alizadeh

IPC: C12Q1/6886 ,  C12Q1/6809 ,  C12Q1/6881 ,  G01N33/50 ,  G16B25/00 ,  G16B25/10 ,  G16B40/10 ,  G16C20/20

CPC classification number: C12Q1/6886 ,  C12Q1/6809 ,  C12Q1/6881 ,  G01N33/5005 ,  G16B25/00 ,  G16B25/10 ,  G16B40/10 ,  G16C20/20 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Q1/6809 ,  C12Q2537/165

Abstract: Methods of deconvolving a feature profile of a physical system are provided herein. The present method may include: optimizing a regression between a) a feature profile of a first plurality of distinct components and b) a reference matrix of feature signatures for a second plurality of distinct components, wherein the feature profile is modeled as a linear combination of the reference matrix, and wherein the optimizing includes solving a set of regression coefficients of the regression, wherein the solution minimizes 1) a linear loss function and 2) an L2-norm penalty function; and estimating the fractional representation of one or more distinct components among the second plurality of distinct components present in the sample based on the set of regression coefficients. Systems and computer readable media for performing the subject methods are also provided.

公开(公告)号：US20240218446A1

公开(公告)日：2024-07-04

申请号：US18557408

申请日：2022-04-27

Applicant: Mission Bio, Inc.

Inventor： Shu Wang ,  Daniel Mendoza ,  Benjamin Schroeder

IPC: C12Q1/6881 ,  C12Q1/6869 ,  G16B30/00

CPC classification number: C12Q1/6881 ,  C12Q1/6869 ,  G16B30/00 ,  C12Q2600/156 ,  C12Q2600/16

Abstract: Methods described herein are useful for evaluating whether cells, that have previously undergone genetic modification, were successfully modified. Methods for determining whether a cell is a genetically modified cell involves a cell calling step and a dynamic normalization step that takes into consideration the variation of sequencing depth and number of working amplicons. Thus, the disclosed methods are able to more accurately and consistently identify successfully modified cells, even in situations where limited reads are available for analysis.

公开(公告)号：US12016905B2

公开(公告)日：2024-06-25

申请号：US17108485

申请日：2020-12-01

Applicant: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION

Inventor： Ki Hoon Ahn ,  Eun Jin Wang

IPC: A61K38/39 ,  A61K31/4439 ,  A61P15/06 ,  C12Q1/6881 ,  G01N33/50 ,  G01N33/68

CPC classification number: A61K38/39 ,  A61K31/4439 ,  A61P15/06 ,  C12Q1/6881 ,  G01N33/5023 ,  G01N33/5044 ,  G01N33/6887 ,  C12Q2600/106

Abstract: Disclosed is a pharmaceutical composition for the prevention or treatment of preterm birth, comprising, as an active ingredient, an agent that inhibits the differentiation of fibroblasts into myofibroblasts in cervix.

公开(公告)号：US20240191297A1

公开(公告)日：2024-06-13

申请号：US18486918

申请日：2023-10-13

Applicant: 10x Genomics, Inc.

Inventor： Cheyenne CHRISTOPHERSON ,  Veronica Emelina GONZALEZ MUÑOZ ,  Joshua GU ,  Albert Dale KIM ,  Yi LUO ,  Meiliana TJANDRA

IPC: C12Q1/6881 ,  C12Q1/6806 ,  C12Q1/6841

CPC classification number: C12Q1/6881 ,  C12Q1/6806 ,  C12Q1/6841 ,  C12Q2600/166

Abstract: The present disclosure relates in some aspects to methods and compositions for quality control (e.g., assessing the level of fixation of a biological sample) and/or optimization of analyte detection in fixed samples. In some embodiments, the method can be used to process a fixed biological sample, the method comprising contacting the fixed biological sample with a nucleic acid stain and/or an actin stain; detecting an optical signal associated with the nucleic acid stain and/or an optical signal associated with the actin stain; comparing the detected optical signal(s) to one or more references to determine the quality of the biological sample. Single cell analysis, spatial array based analysis or in situ analysis can be performed using the processed biological sample.

公开(公告)号：US20240185949A1

公开(公告)日：2024-06-06

申请号：US18529987

申请日：2023-12-05

Applicant: 10x Genomics, Inc.

Inventor： Sreenath KRISHNAN

IPC: G16B20/00 ,  C12Q1/6881 ,  G16B10/00 ,  G16B25/10 ,  G16B30/10 ,  G16B35/20

CPC classification number: G16B20/00 ,  C12Q1/6881 ,  G16B10/00 ,  G16B25/10 ,  G16B30/10 ,  G16B35/20

Abstract: A computer-implemented method is provided for identifying V(D)J cells from at least one data set including a plurality of sequence barcode records from a plurality of single cells. Embodiments of the method include analyzing nucleic acid sequences from nucleic acid sequencing data set(s), comprising comparing a plurality of barcode records in a V(D)J sequencing data set(s) to a plurality of barcode records in a gene expression (GEX) data set(s), to identify a plurality of single V(D)J cells from V(D)J sequencing data set(s), wherein each single V(D)J cell has one or more full length V(D)J contigs.

公开(公告)号：US20240110241A1

公开(公告)日：2024-04-04

申请号：US18256303

申请日：2021-12-07

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

Inventor： Lai Guan Ng ,  Shu Feng Melissa Ng ,  De Li Leonard Tan ,  Florent Benoit Claude Ginhoux

IPC: C12Q1/6881

CPC classification number: C12Q1/6881 ,  C12Q2600/158 ,  G01N2800/52 ,  G01N2800/56

Abstract: The invention relates to a method of detecting and/or characterising an immunosuppressive neutrophil comprising determining and/or measuring the expression of one or more anti-apoptotic markers in a neutrophil population. In an embodiment, the immunosuppressive neutrophil is a polymorphonuclear myeloid-derived suppressor cell (PMNMDSC) and the anti-apoptotic marker is TNF-related apoptosis-inducing ligand (TRAIL)-receptor 3 (TRAILR3/TNFRSF10C) and/or decoy TNF-related apoptosis-inducing ligand (TRAIL)-receptor (dcTRAILR1). Also disclosed are methods of evaluating the progression of a proliferative disease in a subject, methods of evaluating the efficacy of a treatment regimen for a proliferative disease in a subject, methods of treating a proliferative disease in a subject, and kits thereof.

公开(公告)号：US11912749B2

公开(公告)日：2024-02-27

申请号：US17519637

申请日：2021-11-05

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Helen Hoerzer ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: C07K14/47 ,  A61K35/17 ,  A61K39/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/705 ,  C07K14/74 ,  C07K14/82 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C12N5/0783 ,  C12N15/115 ,  C12P21/02 ,  C12Q1/6881 ,  C12Q1/6886 ,  G01N33/569 ,  G01N33/574 ,  A61K38/00 ,  A61K35/12

CPC classification number: C07K14/4748 ,  A61K35/17 ,  A61K39/0011 ,  C07K7/06 ,  C07K7/08 ,  C07K14/4705 ,  C07K14/4738 ,  C07K14/705 ,  C07K14/70539 ,  C07K14/82 ,  C07K16/18 ,  C07K16/28 ,  C07K16/2833 ,  C07K16/30 ,  C07K16/303 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/3038 ,  C07K16/3046 ,  C07K16/3053 ,  C07K16/3069 ,  C07K16/32 ,  C12N5/0636 ,  C12N15/115 ,  C12P21/02 ,  C12Q1/6881 ,  C12Q1/6886 ,  G01N33/56977 ,  G01N33/57449 ,  G01N33/57492 ,  A61K38/00 ,  A61K39/00 ,  A61K2035/124 ,  A61K2039/5158 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/40 ,  C12N2310/16 ,  C12N2320/30 ,  C12N2501/50 ,  C12N2501/998 ,  C12Q2600/158 ,  G01N2333/70539

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.